Options Update: Sepracor volatility low into product pipeline setbacks


Sepracor (NASDAQ: SEPR) is recently down $2.89 to $15 in pre-open trading. SEPR announced that SEP-225289 failed to meet its primary endpoint in a pivotal Phase 2 trial in patients with major depressive disorder. SEPR also announced the FDA has put two Lunesta pediatric studies on hold due to concerns about non-clinical data that could be relevant to the use of Lunesta in children. SEPR over all option implied volatility of 48 is below its 26-week average of 57, according to Track Data, suggesting decreasing price movement.

NASDAQ 100 - QQQQ overall implied volatility at 26; 26-week average is 33.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Symbol Lookup
IndexesChangePrice
DJIA-102.7012,787.76
NASDAQ-26.692,900.54
S&P 500-11.321,340.63

Last updated: February 10, 2012: 09:55 AM

Hot Stocks

General Electric

18.93-0.20(-1.05)

Alcoa

10.35-0.29(-2.73)

Apple Inc

496.74+3.57(+0.72)

Google Inc 'A'

606.28-5.18(-0.85)

Bank of America

8.09-0.09(-1.10)

Wal-Mart Stores

61.56-0.40(-0.65)

Exxon Mobil Corp

83.81-1.07(-1.26)

Ford

12.58-0.11(-0.87)

Citigroup

33.05-0.61(-1.81)

IBM

192.05-1.08(-0.56)

Yahoo

16.10+0.10(+0.62)

Starbucks

48.77-0.43(-0.87)

Microsoft

30.69-0.08(-0.26)

Home Depot

45.05-0.22(-0.49)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1328885754601 ms.